Human Tissues, Lipidomics, and Proteomics Core

人体组织、脂质组学和蛋白质组学核心

• 批准号: 10628988
• 负责人: Jose Orlando Aleman
• 金额: $ 23.97万
• 依托单位: NYU LONG ISLAND SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-05-01 至 2028-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10628988
• 关键词: Adipocytes; Adipose tissue; Apolipoproteins; Apolipoproteins B; Arterial Fatty Streak; Atherosclerosis; Basic Science; Biogenesis; Bioinformatics; Biological Assay; Biology; Body Weight decreased; Cardiovascular Diseases; Cardiovascular system; Catabolism; Centrifugation; Ceramides; Clinical; Communities; Complement; Data; Data Set; Diabetes Mellitus; Family; Fasting; Gastrectomy; Goals; Health; Human; Hypertriglyceridemia; Individual; Institution; Laboratories; Lasers; Lipids; Lipoproteins; Liver; Macrophage; Mass Spectrum Analysis; Metabolism; Methods; Molecular; Molecular Sieve Chromatography; Mus; Obesity; Outcome; Plasma; Procedures; Process; Protein Family; Proteins; Proteomics; Regulation; Research; Research Personnel; Risk; Risk Marker; Risk Reduction; Role; Sampling; Services; Standardization; Systems Biology; Technology; Tissues; Translating; Triglycerides; Ultracentrifugation; analytical method; analytical tool; bioinformatics tool; cardiovascular disorder risk; clinical application; clinical practice; clinical risk; clinically relevant; cohort; cost effectiveness; extracellular vesicles; human tissue; instrumentation; interest; lipidomics; metabolomics; mouse model; novel; particle; phenotypic data; pre-clinical

SUMMARY – HUMAN TISSUES, LIPOPROTEINS, LIPIDOMICS, & PROTEOMICS CORE (C2) The Human Tissues, Lipoproteins, Lipidomics, and Proteomics Core (Core 2, C2) will focus on providing human tissues and analytical capabilities to all three projects to enhance translatability of mouse studies proposed in P1–P3 to clinical practice in humans. In parallel, Core 2 will provide lipoprotein, lipidomic, and proteomic analyses currently not provided by our institutional Metabolomics Core. The cardiovascular research community has shown many important correlations between clinical outcomes and the plasma levels of atherogenic particles of different densities, as determined by ultracentrifugation. More detailed analyses are now uncovering additional risk for cardiovascular disease (CVD) within these particles, such as the content of apoC3 and ceramides. For this PPG, Core 2 will provide a more granular analysis of lipoproteins isolated by centrifugation and size exclusion chromatography through both directed and unbiased lipidomic and proteomic analyses of these particles. In addition, clinical samples (sera, liver, adipose) obtained by the core director will be provided to investigators in all three projects. These services will avoid the need for PPG investigators to maintain the required instrumentation in their own laboratories or use expensive commercial services. By centralizing and standardizing procedures, Core 2 provides a common set of analytical tools to provide a unified understanding of molecular mechanisms involved in pathophysiologic processes of atherosclerosis, macrophage biology, regulation of triglyceride-rich lipoproteins, and obesity. By complementing and integrating with the service provided by Core 1, Core 2 staff also provide bioinformatics support to analyze and interpret proteomic and lipidomic data sets, making Core 2 capabilities available to PPG investigators with little background or expertise in these analytical technologies. A key long-term goal is to integrate quantitative analyses of lipidomic data with functional studies to provide a systems biology view of diabetes-related cardiovascular disease. Core 2 will also develop new analytical methods tailored to specific research objectives of PPG investigators. Specifically, we will obtain and use standards to quantify and discover candidate lipids whose role in atherosclerosis is being investigated. These methods will be extensively used by PPG investigators. Core 2 will offer these services with optimal efficiency and cost-effectiveness, avoiding the need for individuals to pursue such analyses outside the PPG.

摘要-人体组织、脂蛋白、脂质组学和蛋白质组学核心（C2） 人类组织，脂蛋白，脂质组学和蛋白质组学核心（核心2，C2）将重点关注 为所有三个项目提供人体组织和分析能力，以提高可翻译性 将P1-P3中提出的小鼠研究应用于人体临床实践。同时，Core 2将 提供脂蛋白，脂质组学和蛋白质组学分析，目前还没有提供我们的机构 代谢组学核心。心血管研究界已经证明了许多重要的 临床结果与致动脉粥样硬化颗粒血浆水平之间的相关性 不同的密度，如通过超离心测定的。现在有更详细的分析。 揭示这些颗粒中心血管疾病（CVD）的额外风险，例如 apoC 3和神经酰胺的含量。对于该PPG，核心2将提供更详细的分析， 通过离心和尺寸排阻色谱法分离脂蛋白， 以及这些颗粒的无偏脂质组学和蛋白质组学分析。此外，临床样本 (sera、肝脏、脂肪）将提供给这三个中心的研究者 项目这些服务将避免PPG研究者维护所需的 在他们自己的实验室中使用仪器或使用昂贵的商业服务。通过集中 和标准化程序，核心2提供了一套通用的分析工具， 统一认识的分子机制参与的病理生理过程， 动脉粥样硬化、巨噬细胞生物学、富脂蛋白的调节和肥胖。通过 作为对核心1提供的服务的补充和整合，核心2工作人员还提供 生物信息学支持分析和解释蛋白质组学和脂质组学数据集， PPG研究者在这些方面几乎没有背景或专业知识的情况下可获得2种能力 分析技术。一个关键的长期目标是整合脂质组学的定量分析， 功能研究数据，提供糖尿病相关心血管疾病的系统生物学观点 疾病核心2还将开发针对特定研究目标的新分析方法 PPG调查员。具体而言，我们将获得并使用标准来量化和发现 正在研究其在动脉粥样硬化中的作用的候选脂质。这些方法将 PPG研究者广泛使用。Core 2将以最佳效率提供这些服务 和成本效益，避免个人在外部进行此类分析的需要 PPG。